Szoch Stephanie, Boord Christina, Duffy Alison, Patzke Ciera
University of Maryland Medical Center, Baltimore, Maryland. Stephanie Szoch, BSN, RN, OCN®, is a senior clinical nurse II at the University of Maryland Medical Center (UMMC). She chairs the cancer center's Clinical Practice Council and has participated in transitioning vincristine infusions to minibags at UMMC, as well as in other process improvement initiatives to reduce chemotherapy errors. Christina Boord, BSN, RN, OCN®, is a clinical practice and education specialist at UMMC. She sits on several hospital- and system-wide committees working to improve patient-centered care. She is passionate about supporting staff in education and process improvement initiatives to reduce chemotherapy errors. Alison Duffy, PharmD, BCOP, is a clinical specialist in hematology/oncology at UMMC. Dr Duffy is a clinical assistant professor at the University of Maryland School of Pharmacy, as well as the medication safety cochair for the Maryland Society of Health-System Pharmacy. Her interests are in clinical outcomes and practice-based research specifically related to immunocompromised hosts and patients with hematologic malignancies, as well as oncology-related medication safety. Ciera Patzke, PharmD, is a pharmacy resident practicing at UMMC, where she is completing a postgraduate year 2 oncology pharmacy residency through the University of Maryland School of Pharmacy.
J Infus Nurs. 2018 Jul/Aug;41(4):241-246. doi: 10.1097/NAN.0000000000000283.
Blinatumomab has shown great potential for patients with chemotherapy-resistant B-cell acute lymphocytic leukemia. Blinatumomab's toxicity profile includes central nervous system toxicities, as well as cytokine release syndrome. Although neurological toxicities associated with blinatumomab are almost always reversible, early detection and intervention of these toxicities is vital to ensure that patients continue their full course of treatment. Guidelines for the preparation and administration of blinatumomab in both inpatient and outpatient settings, as well as a standardized neurological nursing assessment, were developed to ensure safe and effective administration of blinatumomab.
博纳吐单抗已显示出对化疗耐药的B细胞急性淋巴细胞白血病患者具有巨大潜力。博纳吐单抗的毒性特征包括中枢神经系统毒性以及细胞因子释放综合征。尽管与博纳吐单抗相关的神经毒性几乎总是可逆的，但尽早发现并干预这些毒性对于确保患者完成整个疗程至关重要。制定了住院和门诊环境下博纳吐单抗的配制和给药指南以及标准化的神经护理评估，以确保博纳吐单抗的安全有效给药。
